Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Dr. Rutherford and colleagues hypothesized there would be no impact on PFS when imaging was performed less frequently.
Advertisement
Patients received subcutaneous epcoritamab 48 mg with rituximab plus lenalidomide for twelve cycles.
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma and the nuances involved.
Novel targets are under investigation in several types of hematologic malignancies.
The researchers reported “high rates of durable responses” in most patients who were in high-risk disease subgroups.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Dr. Sehn also explains why the TRIANGLE study is anticipated to change practices surrounding transplant in MCL.
Lenalidomide plus rituximab is “an acceptable chemotherapy-free alternative” to rituximab plus chemo in patients with FL.
The FDA has approved mosunetuzumab-axgb for the treatment of adult patients with R/R follicular lymphoma.
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
The bispecific antibody odronextamab had “compelling” efficacy in patients with relapsed or refractory follicular ...
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.